Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

Home
News Center
LaNova News

LM-102 Obtained China NMPA Clinical Trial Approval

2021-06-23
Share:

LM-102 received China NMPA approval for its China phase I/II clinical study.

Previous

LaNova Medicines Moved to Its New Office at 999 Cailun Road in Zhangjiang Science Park
Next

LM-102 Obtained FDA Clinical Trial Approval and Completed First Patient Dosing